Berberine

NGN Keto + ACV Gummies combine keto support with apple cider vinegar for weight loss, enhancing energy, and improving overall well-being. They promote ketosis, boost metabolism, and improve digestion, with natural ingredients like Ceylon cinnamon, corosolic acid, and saffron bulb extract. Available on the official website, they offer a satisfaction guarantee and are designed to be safe for most dietary preferences.

Wellness brands launch GLP-1 supplements mimicking drugs like Ozempic, but experts warn they don't match prescription potency. Supplements like Lemme's GLP-1 Daily and Hum's Best of Berberine focus on natural ingredients, but cannot replace injectable medications. Pendulum's GLP-1 Probiotic and Arrae's MB-1 also target metabolic health. Consumers must research, as FDA doesn't regulate supplements, and consult doctors to avoid overpromising results.

Berberine, a natural compound found in plants, is gaining attention for its ability to regulate blood sugar levels, offering benefits similar to some diabetes medications. It improves insulin sensitivity and reduces glucose production in the liver via AMPK activation. Beyond blood sugar control, berberine may enhance heart health, aid weight loss, and improve gut health. Research suggests it could be as effective as metformin, but consultation with a healthcare provider is advised. Combining berberine with a balanced diet and lifestyle is crucial for optimal health.

Brand-name injectable drugs like Ozempic and Wegovy, used for weight loss and diabetes control, face high demand and limited supply due to patent protection until 2033-2036. Nonbrand alternatives, including compounded drugs and peptide products, pose risks due to lack of FDA oversight and potential contamination. Pharmaceutical companies like Eli Lilly and Novo Nordisk are under pressure to offer lower-priced options to combat these alternatives, with new GLP-1 agonist drugs expected to enter the market in the coming years.

Brand-name injectable drugs like Ozempic, Wegovy, Mounjaro, and Zepbound, despite their high cost (about $800-$1,000 per month) and limited insurance coverage for weight loss, have become billion-dollar sellers due to their effectiveness in weight loss, blood sugar control, and heart disease risk reduction. The FDA resolved a 2022 shortage of the active ingredient in Mounjaro and Zepbound, but patents on semaglutide and tirzepatide extend until 2033 and 2036, respectively, preventing generic versions. Non-brand alternatives, including dietary supplements and compounded drugs, pose risks due to lack of regulation and testing. Compounding pharmacies offer custom versions but are less regulated than commercial manufacturers. Peptide companies exploit loopholes to sell unapproved versions, often without prescriptions, leading to potential health hazards. Eli Lilly and Novo Nordisk have introduced lower-priced alternatives, and future market entrants may further reduce costs.